You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Inhibitory Activity of Bevacizumab to Differentiation of Retinoblastoma Cells
|
|---|---|
| Published in |
PLOS ONE, March 2012
|
| DOI | 10.1371/journal.pone.0033456 |
| Pubmed ID | |
| Authors |
Jang Won Heo, Jin Hyoung Kim, Chang Sik Cho, Hyoung Oh Jun, Dong Hun Kim, Young Suk Yu, Jeong Hun Kim |
| Abstract |
Vascular endothelial growth factor (VEGF) is a major regulator in retinal and choroidal angiogenesis, which are common causes of blindness in all age groups. Recently anti-VEGF treatment using anti-VEGF antibody has revolutionarily improved the visual outcome in patients with vaso-proliferative retinopathies. Herein, we demonstrated that bevacizumab as an anti-VEGF antibody could inhibit differentiation of retinoblastoma cells without affection to cellular viability, which would be mediated via blockade of extracellular signal-regulated kinase (ERK) 1/2 activation. The retinoblastoma cells expressed VEGFR-2 as well as TrkA which is a neurotrophin receptor associated with differentiation of retinoblastoma cells. TrkA in retinoblastoma cells was activated with VEGF treatment. Interestingly even in the concentration of no cellular death, bevascizumab significantly attenuated the neurite formation of differentiated retinoblastoma cells, which was accompanied by inhibition of neurofilament and shank2 expression. Furthermore, bevacizumab inhibited differentiation of retinoblastoma cells by blockade of ERK 1/2 activation. Therefore, based on that the differentiated retinoblastoma cells are mostly photoreceptors, our results suggest that anti-VEGF therapies would affect to the maintenance or function of photoreceptors in mature retina. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| United States | 1 | 3% |
| South Africa | 1 | 3% |
| Egypt | 1 | 3% |
| Unknown | 27 | 87% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 29% |
| Student > Postgraduate | 4 | 13% |
| Student > Master | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Professor | 3 | 10% |
| Other | 3 | 10% |
| Unknown | 4 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 45% |
| Agricultural and Biological Sciences | 5 | 16% |
| Biochemistry, Genetics and Molecular Biology | 4 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Economics, Econometrics and Finance | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 5 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 March 2012.
All research outputs
#18,305,470
of 22,663,969 outputs
Outputs from PLOS ONE
#153,769
of 193,506 outputs
Outputs of similar age
#124,204
of 160,668 outputs
Outputs of similar age from PLOS ONE
#2,849
of 3,709 outputs
Altmetric has tracked 22,663,969 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 193,506 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,668 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3,709 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.